Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082069 · ClinicalTrials.gov registry record · Phase 1
Invaplex 50 Vaccine Dose-Ranging
A Phase 1 study of Diarrhea, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00082069 is a Phase 1 study of Diarrhea that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 32 participants, below the 156-participant average among 24 other Diarrhea trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00082069, a Phase 1 study of Diarrhea, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The vaccine is given as a nose spray. Volunteers will receive a 3-dose vaccination with doses spaced two weeks apart. Volunteers will be assigned to a vaccination group based on their order of enrollment with consideration of their availability to complete the necessary vaccinations and follow-up visits.
Conditions Studied
Interventions
- BIOLOGICAL Shigella flexneri 2a Invaplex 50
Study Locations (1)
Maryland
- Walter Reed Army Institute of Research - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082069
The ClinicalTrials.gov registry entry for NCT00082069 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 156-participant average among 24 other Diarrhea trials with a reported enrollment target (79% lower). The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diarrhea appearing as the primary indexed condition, and to 1 intervention - of which Shigella flexneri 2a Invaplex 50 is the first listed.
NCT00082069 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00082069 about?
NCT00082069 is a clinical study titled "Invaplex 50 Vaccine Dose-Ranging". The vaccine is given as a nose spray. Volunteers will receive a 3-dose vaccination with doses spaced two weeks apart. Volunteers will be assigned to a vaccination group based on their order of enrollment with consideration of their availability to complete the necessary vaccinations and follow-up vi...
What is the current status of trial NCT00082069?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2004-04. Estimated completion is 2006-11.
What conditions does trial NCT00082069 study?
This clinical trial studies the following conditions: Diarrhea.
What interventions are being tested in trial NCT00082069?
The interventions under investigation include: Shigella flexneri 2a Invaplex 50 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00082069?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00082069 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diarrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
RECRUITING · Phase 1
-
First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults
RECRUITING · Phase 1
-
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
RECRUITING · Phase 1
-
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
COMPLETED · Phase 1
-
Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]
COMPLETED · Phase 1
-
GI Alpha-Gal Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.